ClinicalTrials.gg
CompletedNCT02937389Updated Apr 5, 2023

Endoscopic Evaluation for Predicting the Complications Related to Gastric Conduit After Esophagectomy

An observational study in Esophageal Neoplasms, Constriction and Anastomotic Leak, sponsored by Nagasaki University. Completed at 1 site in Japan. Open to participants aged 20 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Nagasaki University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
20 Years to 84 Years
Sex
All
01

Study summary

Gastric conduit ischemia or anastomotic breakdown after esophagectomy with cervical esophagogastrostomy often cause severe complications, such as leakage, necrotic organs, and strictures. Thus, the purpose of this study is the safety and efficacy of endoscopic evaluation about reconstructive organs after esophagectomy. The investigators evaluate endoscopic predictions using classifications in acute phase after esophagogastrostomy.

Read the detailed description

The development and improvement of thoracoscopic esophagectomy (TE) reduced the severe pulmonary complication after esophagectomy. However, the postoperative complications relative to gastric conduit reconstruction are still common issues after esophagectomy. The ischemia of the proximal portion of the graft predisposes these patients to a high incidence of anastomotic complications after esophagectomy. Less commonly, severe graft ischemia can lead to transmural necrosis. Thus, early diagnosis of ischemic reaction may provide the suitable postoperative management and therapeutic intervention to prevent leakage, strictures and necrosis. Thus, the purpose of this study is the safety and efficacy of endoscopic evaluation about reconstructive organs after esophagectomy. The investigators evaluate endoscopic predictions using classifications in acute phase after esophagogastrostomy.

02

Conditions studied

  • Esophageal Neoplasms
  • Constriction
  • Anastomotic Leak
  • Ischemia
03

In context

Esophageal Neoplasms

1,873 studies on the registry are indexed under Esophageal Neoplasms; 501 are open to participants now.

This study's enrollment of 60 is below the median of 200 across 432 observational studies indexed under Esophageal Neoplasms.

Browse Esophageal Neoplasms studies →

Lead sponsor

Nagasaki University is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergo an esophagectomy with reconstruction by a gastric pull-up for malignant or end-stage benign esophageal disease. The patients have a cervical esophagogastrostomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Malignant or end-stage benign esophageal disease. Esophagectomy with reconstruction by a gastric pull-up.

Exclusion criteria

Exclusion Criteria:

  • Severe heart failure and pulmonary dysfunction Severe renal and liver dysfunction Allergenic history Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testPatients after esophagectomy

    Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.

06

What researchers measure

Primary outcomes

  1. The classification of gastric conduit ischemia by endoscopic findings predicts the major complications of gastric conduit (strictures, leakage, necrosis)

    Time frame: From 1 to 29 days after esophagectomy

Secondary outcomes

  1. Biological examination of the mucosal biopsy of gastric conduit as assessed by the ischemia related RNA copy number

    Time frame: From 1 to 15 days after esophagectomy

  2. Biological examination of the mucosal biopsy of gastric conduit as assessed by the scoring system for immunohistochemical staining

    The scoring system refer to the article entitled a scoring system for immunohistochemical staining: consensus report of the task force for basic research of the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group

    Time frame: From 1 to 15 days after esophagectomy

  3. Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number

    Time frame: From 1 to 15 days after esophagectomy

07

Study locations

1 site
  • Nagasaki University Hospital
    Nagasaki, 852-8501, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02937389
Lead sponsor
Nagasaki University
Responsible party
Kobayashi Shinichiro (Principal Investigator in department of Surgery, Nagasaki University) — Principal investigator
First posted
Oct 18, 2016
Start date
May 2015
Primary completion
Nov 2018
Completion
Nov 2019
Last update
Apr 5, 2023

Study contacts

Shinichhiro Kobayashi, M.D.
study director · Nagasaki University Graduate School of Biomedical Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion